New treatment strategies for hepatitis c infection

Basit Öğe Kaydı
dc.contributor.authorErmiş, Fatih
dc.contributor.authorTaşçı, Elif Şenocak
dc.date.accessioned2020-04-30T23:19:36Z
dc.date.available2020-04-30T23:19:36Z
dc.date.issued2015
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionWOS: 000439204000006en_US
dc.descriptionPubMed: 26301052en_US
dc.description.abstractHepatitis C infection can lead to cirrhosis and hepatocellular carcinoma and it is an important cause of mortality and morbidity. Achieving a sustained virological response has been the major aim for decades. Interferon treatment was the primarily developed therapy against the infection. Addition of the guanosine analog ribavirin to stop viral RNA synthesis increased the response rates as well as the adverse effects of the treatment. The increasing demands for alternative regimens led to the development of direct-acting antivirals (DAAs). The approval of sofosbuvir and simeprevir signaled a new era of antiviral treatment for hepatitis C infection. Although the majority of studies have been performed with DAAs in combination with interferon and resulted in a decrease in treatment duration and increase in response rates, the response rates achieved with interferon-free regimens provided hope for patients ineligible for therapy with interferon. Most DAA studies are in phase. leading to phase.. In the near future more DAAs are expected to be approved. The main disadvantage of the therapy remains the cost of the drugs. Here, we focus on new treatment strategies for hepatitis C infection as well as agents targeting hepatitis C virus replication that are in clinical development.en_US
dc.identifier.doi10.4254/wjh.v7.i17.2100en_US
dc.identifier.endpage2109en_US
dc.identifier.issn1948-5182
dc.identifier.issue17en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage2100en_US
dc.identifier.urihttps://doi.org/10.4254/wjh.v7.i17.2100
dc.identifier.urihttps://hdl.handle.net/20.500.12684/3800
dc.identifier.volume7en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBaishideng Publishing Group Incen_US
dc.relation.ispartofWorld Journal Of Hepatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDirect-acting antiviralsen_US
dc.subjectEradicationen_US
dc.subjectGenotypeen_US
dc.subjectHepatitis C virus infectionen_US
dc.subjectInterferon-freeen_US
dc.subjectTreatmenten_US
dc.titleNew treatment strategies for hepatitis c infectionen_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
3800.pdf
Boyut:
926.1 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu